Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Amgen is running a confirmatory phase 3 trial called CodeBreak 200 that is comparing Lumakras to the chemotherapy agent docetaxel in previously-treated patients with KRAS G12C-mutated NSCLC, with ...

Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher operating margin ...

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

Amgen has now filed sotorasib with the FDA, based on data from a phase 2 trial in patients with advanced or metastatic KRAS G12C mutated non-small cell lung cancer. Mirati, a biotech from ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

KRAS G12C allele amplification or copy number gain were the ... A-CT reports personal fees from AMGEN, during the conduct of the study; personal fees and non-financial support from Novartis, personal ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...